Table 1 Patients characteristics
Characteristic | ICIs plus anlotinib No (%) |
|---|---|
No of total patients | 30 |
Gender | |
Male | 25(83.33%) |
Female | 5(16.67%) |
Age(years) | |
Median age(range) | 63.5(range,36–79) |
<65 | 16(53.33%) |
≥ 65 | 14(46.67%) |
Smoking History | |
Non-smoker | 5(16.67%) |
Former smoker | 25(83.33%) |
ECOG performance status | |
0 | 10(33.33%) |
1 | 20(66.67%) |
Histology | |
Squamous cell carcinoma | 15(50.00%) |
Adenocarcinoma | 15(50.00%) |
Stage | |
IIIb-IIIc | 5(16.67%) |
IV | 25(83.33%) |
Metastatic | |
Liver | 5(16.67%) |
Brain | 4(13.33%) |
Bone | 10(33.33%) |
Lung | 16(53.33%) |
Pleural metastasis | 4(13.33%) |
PD-L1 status test | |
Data unavailable | 9(30.00%) |
0% | 5(16.67%) |
1–49% | 6(20.00%) |
≥ 50% | 10(33.33%) |
PFS | |
≥ 6个月 | 15(50.00%) |
<6个月 | 15(50.00%) |
Efficacy evaluation | |
PR | 6(20.00%) |
SD | 17(56.67%) |
PD | 7 (23.33%) |